Navigation Links
Immune Design Grants Adjuvant License to MedImmune
Date:10/26/2010

SEATTLE, Oct. 26 /PRNewswire/ -- Immune Design Corp. (IDC), a privately held biotechnology company developing novel vaccines and immunotherapies for infectious disease and cancer, announced today that it has entered into a license and development agreement with MedImmune for the use and commercialization of IDC’s proprietary Glucopyranosyl Lipid Adjuvant (GLA) as a component in vaccines for select infectious diseases.

"We are pleased to enter into this license with MedImmune as one of the world's leading vaccine research-based pharmaceutical and healthcare companies," commented IDC Executive Chairman Dr. Bruce Carter.  "This relationship fits very well with IDC’s business model to advance the development of GLA and enable innovative vaccine products that we believe will provide significant benefit in areas of unmet need while maintaining our commitment to global access."

Under the terms of the license agreement, IDC grants MedImmune exclusive worldwide rights to research, develop, use, and commercialize the GLA adjuvant in vaccines for specific indications.  In return, IDC will receive an upfront licensing fee and potential development, regulatory and commercial milestones totaling $212M, in addition to royalty payments on sales of marketed products.  

GLA is a toll-like receptor 4 (TLR-4) agonist which IDC has advanced into early clinical stage development.  The small molecule adjuvant has several important features including a pure synthetic composition with straightforward manufacturing and long term stability, a rational design for optimal activation of human dendritic cells, compatibility with antigens in multiple formulations, and a well established safety profile.  

About Immune Design Corp.: Immune Design Corp. is a privately held biotechnology company based in Seattle, WA.  IDC brings together some of the world’s leaders in the field of molecular immunology to develop vaccines for the prevention and treatment of infectious and malignant disease.  The company employs leading edge technologies to target and activate dendritic cells for effective antigen presentation to direct the desired immune response.  For more information, go to www.immunedesign.com.  

About MedImmune:MedImmune, the worldwide biologics unit for AstraZeneca PLC (NYSE: AZN; LSE: AZN.L), has approximately 3,300 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising drug candidates, MedImmune strives to deliver life-changing products, a rewarding career to our employees and a tireless commitment to improving patient health. For more information, visit MedImmune’s website at www.medimmune.com.Media Relations: Immune Design Corp. Cassie D. Ostrander (206) 826-7901media@immunedesign.com
'/>"/>

SOURCE Immune Design Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
2. Peptimmune Presentation at Upcoming World Congress on Treatment and Research in Multiple Sclerosis
3. EUPROBIO 2008 Presentation to Highlight Latest Immune Research
4. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
5. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
6. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
7. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
8. Peptimmune Presentations at Upcoming Events
9. Protein-printing technique gives snapshots of immune system defense
10. Visualizing asthma-causing immune cells at work
11. AutoImmune Inc. Reports 2008 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... Kathy Goin ... of Clinical Operations. She brings years of expertise in establishing and leading clinical ... foundation as a licensed occupational therapist, through a variety of leadership roles in ...
(Date:5/22/2017)... ... May 22, 2017 , ... ... other leaders of the Maryland Biohealth community in developing and issuing recommendations to ... 3 U.S. BioHealth Innovation Hub by 2023. , The recommendations ...
(Date:5/19/2017)... PA (PRWEB) , ... May 19, 2017 , ... ... its QED Proof-of-Concept Program. Academic researchers with technologies ripe for commercialization, and ... New Jersey and Delaware, are encouraged to submit proposals. QED, now in its ...
(Date:5/18/2017)... ... May 17, 2017 , ... ... its scientific power by providing investigators access to a high-profile scientific advisory ... the scientific advisory board. “We are committed to offering superior services and ...
Breaking Biology Technology:
(Date:4/11/2017)... , Apr. 11, 2017 Research and ... Market 2017-2021" report to their offering. ... The global eye tracking market to grow at a ... report, Global Eye Tracking Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
(Date:3/30/2017)... , March 30, 2017 The research team ... for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint ... new realm of speed and accuracy for use in identification, crime ... affordable cost. ... A ...
Breaking Biology News(10 mins):